Hyperfine, Inc.
NASDAQ:HYPRMedical - Devices
+$0.22 today
- Market cap
- $51.10M
- Beta
- 1.38
- P/E (TTM)
- -4.5
- EPS (TTM)
- -$0.36
Volume 1.16M
Average 0.60M
HYPR Revenue
Total income from selling goods and services before any costs are deducted; the top line of the income statement.
Hyperfine, Inc.NASDAQ: HYPR
Revenue · Q1 FY2026 · quarter ended Mar 2026
Revenue growth accelerates
Q1 FY2026 revenue of $3.9M rose 82.6% year over year, ahead of the +30.7% change in trailing-twelve-month revenue. Sequentially, it fell 26.3% from the prior quarter. Over 3 fiscal years it compounded at +25.8% a year.
Context
- Revenue increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether revenue reaches the consensus estimate from 3 analysts of $20.49M (+51.1%) for the fiscal year ending Dec 2026, a step up from the +5.2% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $3.9M-26.3% QoQ
- Last fiscal yearDec 2025
- $13.56M+5.2% YoY
- LTMMar 2026
- $15.33M+30.7% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +82.6% | +53.4% | -29.3 pp |
| 1 year | +5.2% | +51.1% | +45.9 pp |
| 3-year CAGR | +25.8% | +40.9% | +15.1 pp |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Revenue history
USD · from the income statement
- Latest · FY2025
- 13.56M USD
- Year-over-year change
- +5.2%
- 4-year CAGR
- +73.5%
| Period | Period end | Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 13.56M | +5.2% |
| FY2024 | 2024-12-31 | 12.89M | +16.8% |
| FY2023 | 2023-12-31 | 11.03M | +61.9% |
| FY2022 | 2022-12-31 | 6.81M | +355.5% |
| FY2021 | 2021-12-31 | 1.5M | — |
Revenue vs competitors
How HYPR compares with its peers on the latest reported figures
- HYPR's LTM Mar 2026 revenue of $15.33M is the 4th highest of the 7 companies compared; the peer median is $36.21M.
- Its year-over-year change of +30.7% is the highest of 5, against a peer median of +1.1%.
- Over three fiscal years its annual growth of +25.8% compares with a peer median of +10.6%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Mar 2026 | $105.34M | +2.3% | +2.3% | |
| LTM Mar 2026 | $88.55M | +1.2% | +19.0% | |
| LTM Mar 2026 | $72.35M | +1.0% | +27.7% | |
| LTM Mar 2026 | $15.33M | +30.7% | +25.8% | |
| FY2025 | $64K | -99.8% | — | |
| LTM Mar 2026 | $0 | — | — | |
IMAImageneBio Inc | LTM Mar 2026 | $0 | — | -62.9% |
| Peer median (excluding HYPR) | $36.21M | +1.1% | +10.6% | |
Competitors are the stored peer set for HYPR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 1.5M | 6.81M | 11.03M | 12.89M | 13.56M |
| Cost of Revenue | 2.66M | 5.91M | 6.28M | 7M | 6.81M |
| Gross Profit | (1.17M) | 907K | 4.76M | 5.89M | 6.75M |
| Gross Margin | -78.0% | 13.3% | 43.1% | 45.7% | 49.8% |
| Research & Development | 25.84M | 28.16M | 22.49M | 22.5M | 17.45M |
| Selling, General & Admin | 37.86M | 46.63M | 30.38M | 26.62M | 26.39M |
| Operating Expenses | 63.7M | 74.78M | 52.87M | 49.12M | 43.84M |
| Depreciation & Amortization | 726K | 1.02M | 1.05M | 1.01M | 2.2M |
| EBITDA | (64.13M) | (72.15M) | (43.18M) | (39.71M) | (33.37M) |
| EBITDA Margin | -4286.4% | -1058.8% | -391.4% | -308.1% | -246.1% |
| Operating Income | (64.87M) | (73.87M) | (48.12M) | (43.22M) | (37.09M) |
| Operating Margin | -4336.1% | -1084.2% | -436.1% | -335.3% | -273.4% |
| Interest Income | 18K | 761K | 3.84M | 2.49M | 1.02M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 17K | 710K | 3.88M | 2.5M | 1.51M |
| Income Before Tax | (64.85M) | (73.16M) | (44.24M) | (40.72M) | (35.57M) |
| Pre-Tax Margin | -4335.0% | -1073.7% | -401.0% | -315.9% | -262.3% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (64.83M) | (73.16M) | (44.24M) | (40.72M) | (35.57M) |
| Net Margin | -4333.8% | -1073.7% | -401.0% | -315.9% | -262.3% |
| EPS (Basic) | (0.92) | (1.04) | (0.62) | (0.56) | (0.43) |
| EPS (Diluted) | (0.92) | (1.04) | (0.62) | (0.56) | (0.43) |
| Weighted Avg Shares | 70.33M | 70.45M | 71.32M | 72.41M | 94.2M |
| Weighted Avg Shares (Diluted) | 70.33M | 70.45M | 71.32M | 72.41M | 94.2M |
Hyperfine, Inc.
NASDAQ:HYPR
Intrinsic Alpha fair value
Locked
Current Price
$0.56
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.